352 results on '"van den Berkmortel, Franchette"'
Search Results
2. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial
3. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
4. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
5. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
6. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
7. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
8. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
9. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
10. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
11. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
12. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
13. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
14. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
15. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
16. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
17. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
18. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
19. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
20. A prediction model for response to immune checkpoint inhibition in advanced melanoma
21. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
22. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
23. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
24. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study
25. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
26. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.
27. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
28. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting
29. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
30. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
31. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
32. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
33. The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer – A longitudinal follow-up study
34. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review
35. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
36. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
37. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
38. Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status
39. Insights into the counseling of patients with stage III melanoma for adjuvant treatment
40. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
41. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
42. Functional status decline in older patients with breast and colorectal cancer after cancer treatment: A prospective cohort study
43. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
44. Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice
45. Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
46. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials
47. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
48. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
49. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
50. Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.